http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2898217-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_48931f61f65ee74fda8bcfb3feded8ec |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5f3966ad8653795688d2a805e179d19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f781177559db2beb94c082ee41d995d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21601e8fcbc42fcd8d80ea23cec13e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50c7776e7f9be47181aab32c8db21874 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9659c17fca96bfe3003163c97b03d9f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0255c69dabb7af43821fcf6fb9e86cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ef202d0bf8ce561efe72a5efc4bd5d7 |
| publicationDate | 2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2898217-T3 |
| titleOfInvention | Cyclic sulfonamide compounds and methods of using the same |
| abstract | A compound of Formula I: **(See formula)** or a pharmaceutically acceptable salt thereof, wherein: w is 2; R1 is phenyl or pyridyl, each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -OH, -CN, -NO2, oxo, hydrazino, formyl, azido, silyl, siloxy, -S(O)4-C1-6 alkyl, -NRaRb, -NRc-S(O)t-C1-6 alkyl, -S(O)t-NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, RaRbN-C1-6 alkyl-, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkoxy-, RaRbN-C1-6 alkoxy -, C1-6alkoxy, C1-6alkyl, -C(O)NRaRb, -C(O)-C1-6alkyl, -C(O)OH and -C(O)O-C1-6alkyl; R2 is hydrogen; R3 is selected from the group consisting of **(See formula)** wherein: R4 is hydrogen or C1-6 alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, -OH, - CN, -S(O)q-C1-6 alkyl, -NRaRb, -NRc-S(O)t-C1-6 alkyl, -S(O)t-NRaRb, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy - C(O)NRaRb, -C(O)-C1-6 alkyl, formyl, -C(O)OH, -C(O)O-C1 alkyl -6, benzyloxy, C1-4alkoxyphenyl, pyrrolidinyl, morpholinyl, tetrahydrofuran, and triazolyl; R5 is hydrogen or C1-6 alkyl optionally substituted with a substituent selected from the group consisting of halogen, -OH, C1-6 alkoxy, -NRaRb and RaRbN-C1-4 alkyl; R6 is hydrogen or C1-6 alkyl; R33 is independently selected for each occurrence from the group consisting of: halo, -OH, -CN, -NO2, oxo, hydrazino, formyl, azido, silyl, siloxy, -S(O)q-C1-6alkyl, -NRaRb , -NRc-S(O)t-C1-6 alkyl, -S(O)t-NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl C1-6 haloalkyl, C1-hydroxyalkyl -6, RaRbN-C1-6alkyl-, C1-6alkoxy, C1-6haloalkoxy, C1-6hydroxyalkoxy-, RaRbN-C1-6alkoxy-, C1-6alkoxyC1-6alkyl, -C(O)NRaRb, -C(O)-C1-6 alkyl, -C(O)OH, and -C(O)O-C1-6 alkyl, and a 5-6 membered monocyclic heteroaryl with one, two or three heteroatoms selected from the group consisting of O, N and S, where phenyl and 5-6 membered monocyclic heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of: halo, -OH, -CN, -NO2, oxo, hydrazino, formyl, azido, silyl, siloxy, -S(O)q-C1-6 alkyl, -NRaRb, -NRc-S(O)t-C1-6 alkyl, -S(O)t-NRaRb, C1-6 alkyl, C2-6 alkenyl, C2 alkynyl -6, C3-6 cycloalkyl, C1-6 haloalkyl C1-6 hydroxyalkyl, RaRbN-C1-6 alkyl-, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkoxy-, RaRbN-C1-6 alkoxy-, alkoxy C1-6C1-6alkyl, -C(O)NRaRb, -C(O)-C1-6alkyl, -C(O)OH and -C(O)O-C1-6alkyl; R34 is selected from the group consisting of hydrogen, C1-4alkyl, and C1-4hydroxyalkyl; Ra and Rb are independently hydrogen or C1-6 alkyl; or Ra and Rb can be taken together with the nitrogen to which Ra and Rb are attached to form **(See formula)** Rc is hydrogen or C1-6 alkyl; for each presence, q is 0, 1 or 2, for each presence, t is 1 or 2; r is 0, 1 or 2; r2 is 0, 1, 2 or 3; provided that: when R3 is thiophen-2-yl or furan-2-yl, r2 is 1, 2 or 3; when R3 is pyrazol-4-yl, in at least one instance, R33 is other than C1-6alkyl; and when R3 is phenyl, at least one of R35, R36 and R37 is other than halo and C1-6 alkoxy. |
| priorityDate | 2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 782.